Summit Therapeutics

Yahoo Finance • 6 days ago

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binar... Full story

Yahoo Finance • 8 days ago

This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market

Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and a $45 price target.... Full story

Yahoo Finance • 9 days ago

Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch

Summit Therapeutics stock crashed Friday after the company said its lung cancer treatment didn't pass muster at an interim analysis. Continue Reading... Full story

Yahoo Finance • 9 days ago

Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026

(RTTNews) - Summit Therapeutics Inc. (SMMT) reported financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided clinical and operational progress for its lead candidate, Ivonescimab. Company Pro... Full story

Yahoo Finance • 20 days ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • last month

Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed

Summit Therapeutics recently presented Phase III data for its investigational bispecific antibody ivonescimab at the European Lung Cancer Congress in Copenhagen, showing improved intracranial progression-free survival in EGFR‑mutated non-s... Full story

Yahoo Finance • 2 months ago

Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer... Full story

Yahoo Finance • 2 months ago

Summit Therapeutics plans interim PFS analysis for HARMONi-3 squamous cohort in Q2 2026 as clinical pipeline expands

Earnings Call Insights: Summit Therapeutics Inc. (SMMT) Q4 2025 MANAGEMENT VIEW * Mahkam Zanganeh, Co-CEO, President & Director, highlighted ongoing accomplishments and "the growing positive data sets and support around ivonescimab, a... Full story

Yahoo Finance • 2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase I... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough

Summit Therapeutics (NASDAQ:SMMT) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish. The stock had... Full story

Yahoo Finance • 3 months ago

Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In?

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most oversold NASDAQ stocks to invest in. On February 2, H.C. Wainwright reaffirmed a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) with a price target of $40.00. The firm views F... Full story

Yahoo Finance • 3 months ago

China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse.

U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the rivalry? Continue Reading... Full story

Yahoo Finance • 3 months ago

One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens

On February 2, Hong Kong-based Apeiron Capital Limited disclosed in a U.S. Securities and Exchange Commission filing that it sold its entire position in the iShares Ethereum Trust ETF(NASDAQ:ETHA) in an estimated $8.99 million trade during... Full story

Yahoo Finance • 5 months ago

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) and set a $1... Full story

Yahoo Finance • 5 months ago

Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?

Key Points In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion. The company doesn't genera... Full story

Yahoo Finance • 5 months ago

2 Monster Stocks in the Making to Buy and Hold

Key Points SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential. 10 stocks we like better than SoFi Technologies › It's not possible to go back... Full story

Yahoo Finance • 7 months ago

Apple foldable iPad may be delayed amid development snag: report

[Close Up Of Business Colleagues Using Digital Tablet Together] Tom Werner * A foldable version of the iPad may be delayed, as Apple (NASDAQ:AAPL [https://seekingalpha.com/symbol/AAPL]) has reportedly hit some snags in developing the ta... Full story

Yahoo Finance • 7 months ago

SA analyst upgrades/downgrades: TSLA, MSFT, AAPL, SMMT

[Stock market trading, financial data graph chart, data visualization, Business arrow graph chart] Rasi Bhadramani Recent Seeking Alpha analyst actions have revealed significant shifts in market outlooks for key technology and healthcare... Full story

Yahoo Finance • 7 months ago

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

​Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-G... Full story

Yahoo Finance • 7 months ago

Stocks making the biggest moves midday: Apple, Cleveland-Cliffs, Oracle, KLA, Tempus AI and more

Check out the companies making the biggest moves midday: Apple — The Tim Cook-led company climbed 4% after the iPhone 17 series outsold the iPhone 16 series in China and the U.S. in the first 10 days of availability, according to Counterpo... Full story